Trial
NCT02449655
Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Samsung Medical Center
Collaborators
—
Condition
Advanced Gastric Adenocarcinoma
Intervention
AZD5363
Why stopped
lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-20